Fatemeh Akhlaghi

Fatemeh Akhlaghi

Auto-generated profile, based on publicly available information

Fatemeh Akhlaghi

Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2017 in Drug Metabolism Reviews
Verified
Journal Article
Closed access
ECEnoch Cobbina
Enoch Cobbina
FAFatemeh Akhlaghi
Fatemeh Akhlaghi
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disorders. It is defined by the presence of steatosis in more than 5% of hepatocytes with little or no alcohol consumption. Insulin resistance, the metabolic syndrome or type 2 diabetes and genetic variants of PNPLA3 or TM6SF2 seem to play a role in the pathogenesis of NAFLD. The pathological progression of NAFLD follows tentatively a “three-hit” process namely steatosis, lipotoxicity and inflammation. The presence of steatosis, oxidative stress and inflammatory mediators like TNF-α and IL-6 has been implicated in the alterations of nuclear factors such as CAR, PXR, PPAR-α in NAFLD. These factors may result in altered expression and activity of drug metabolizing enzymes (DMEs) or transporters. Existing evidence suggests that the effect of NAFLD on CYP3A4, CYP2E1 and MRP3 is more consistent across rodent and human studies. CYP3A4 activity is down-regulated in NASH whereas the activity of CYP2E1 and the efflux transporter MRP3 is up-regulated. However, it is not clear how the majority of CYPs, UGTs, SULTs and transporters are influenced by NAFLD either in vivo or in vitro. The alterations associated with NAFLD could be a potential source of drug variability in patients and could have serious implications for the safety and efficacy of xenobiotics. In this review, we summarize the effects of NAFLD on the regulation, expression and activity of major DMEs and transporters. We also discuss the potential mechanisms underlying these alterations.


16 February 2011 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
MDMiroslav Dostalek
Miroslav Dostalek
MCMichael H. Court
Michael H. Court
BYBingfang Yan
Bingfang Yan
FAFatemeh Akhlaghi
Fatemeh Akhlaghi
BACKGROUND AND PURPOSEPatients with diabetes mellitus require pharmacotherapy with numerous medications. However, the effect of diabetes on drug biotransformation is not well understood. Our goal was to investigate the effect of diabetes on liver cytochrome P450 3As, the most abundant phase I drug‐metabolizing enzymes in humans.EXPERIMENTAL APPROACHHuman liver microsomal fractions (HLMs) were prepared from diabetic (n= 12) and demographically matched nondiabetic (n= 12) donors, genotyped forCYP3A4*1BandCYP3A5*3polymorphisms. Cytochrome P450 3A4, 3A5 and 2E1 mRNA expression, protein level and enzymatic activity were compared between the two groups.KEY RESULTSMidazolam 1′‐ or 4‐hydroxylation and testosterone 6β‐hydroxylation, catalyzed by P450 3A, were markedly reduced in diabetic HLMs, irrespective of genotype. Significantly lower P450 3A4 protein and comparable mRNA levels were observed in diabetic HLMs. In contrast, neither P450 3A5 protein level nor mRNA expression differed significantly between the two groups. Concurrently, we have observed increased P450 2E1 protein level and higher chlorzoxazone 6‐hydroxylation activity in diabetic HLMs.CONCLUSIONS AND IMPLICATIONSThese studies indicate that diabetes is associated with a significant decrease in hepatic P450 3A4 enzymatic activity and protein level. This finding could be clinically relevant for diabetic patients who have additional comorbidities and are receiving multiple medications. To further characterize the effect of diabetes on P450 3A4 activity, a well‐controlled clinical study in diabetic patients is warranted.

24 May 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
RJRohitash Jamwal
Rohitash Jamwal
SMSuzanne M de la Monte
Suzanne M de la Monte
KOKen Ogasawara
Ken Ogasawara
SASravani Adusumalli
Sravani Adusumalli
BBBenjamin Joseph Barlock
Benjamin Joseph Barlock
FAFatemeh Akhlaghi
Fatemeh Akhlaghi

1 January 2002 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
FAFatemeh Akhlaghi
Fatemeh Akhlaghi
ATAndrew K. Trull
Andrew K. Trull

30 April 2013 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
KOKen Ogasawara
Ken Ogasawara
SCShripad D. Chitnis
Shripad D. Chitnis
RGReginald Y. Gohh
Reginald Y. Gohh
UCUwe Christians
Uwe Christians
FAFatemeh Akhlaghi
Fatemeh Akhlaghi